BioGaia AB (0GTN) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of BioGaia AB SEK 46.82, price SEK 114, upside -59.0%, quality 64 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch BioGaia AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments.
Show more
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. Its Adult Health segment provides gut health tablets, bone health tablets, and oral health lozenges, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment offers packaging solutions. It sells its products through distribution partners or through its own distribution channels. The company was incorporated in 1990 and is headquartered in Stockholm, Sweden.
Stock analysis
BioGaia AB (0GTN) currently trades at kr 114.20, while our model-based Fair Value estimate is kr 46.82, 59.0% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of kr 61.14 per share, and 0 of the 24 models we run sit above the kr 114.20 price.
Bear case: the Dividend Discount group reads lowest at kr 9.68, and 24 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: kr 35.12 (bear) to kr 58.53 (bull), the price of kr 114.20 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
BioGaia AB reported revenue of 747M SEK in FY2020 versus 535M SEK in FY2016, a compound +8.7%/yr. Reported net income was 180M SEK in FY2020, compounding −5.7%/yr from FY2016.
Key figures
Market cap 9.8B SEK (≈ $973M) · P/S ratio 6.18 · Dividend yield 1.4% · Net margin 24.1% · Return on equity 30.8% · Return on assets (EBIT) 34.3% · Operating margin 28.4% · Revenue (TTM) 1.6B SEK.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 55 out of 100 (low confidence).
What moves the price
The share trades about 16% below its 52-week high and 19% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −59%, 0GTN screens richer than that median.
Fair Value models
Bear kr 35.12Fair Value kr 46.82Bull kr 58.53
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.69/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−2.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.7%
’16
’17
’18
’19
’20
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
37.3% (2016) → 30.5% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks
Beats the industry median on 8/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score64 · Top 25%
Profitability
Return on equity (TTM)30.8% · Top 25%
Return on assets19.8% · Top 25%
Net margin (TTM)22.0% · Top 25%
Operating margin (TTM)28.4% · Top 25%
Growth and dividend
Revenue growth8.9% · Above median
Dividend yield (TTM)1.4% · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "BioGaia AB Fair Value". https://www.fairvalue-calculator.com/stock/0GTN
Frequently asked questions
Is BioGaia AB (0GTN) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 46.82 versus a price of kr 114.20, about −59% upside (overvalued).
What is the fair value of 0GTN?
Our model-based fair value for BioGaia AB is kr 46.82 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 114.20.
What is the quality score of 0GTN?
BioGaia AB has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BioGaia AB (0GTN)?
Our model-based price target is the fair value of kr 46.82 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario kr 35.12, optimistic scenario kr 58.53. It is a calculation from audited fundamentals, not an analyst target.
What is the BioGaia AB stock forecast for 2026?
Our models put fair value at kr 46.82, about −59% upside versus a price of kr 114.20 (overvalued). Cautious scenario kr 35.12, optimistic scenario kr 58.53. The calculation is refreshed regularly with new filings.
What is the revenue of BioGaia AB (0GTN)?
BioGaia AB reported trailing-twelve-month revenue of about 1.6B SEK (latest available figure, as of Sep 24, 2026).
Does BioGaia AB pay a dividend?
BioGaia AB currently shows a dividend yield of about 1.44% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of BioGaia AB (0GTN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BioGaia AB it is kr 46.82 per share (as of Sep 24, 2026), against a price of kr 114.20. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is BioGaia AB stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0GTN trades above its calculated fair value: price kr 114.20, fair value kr 46.82, a gap of about −59% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0GTN?
No. The price is what the market pays today (kr 114.20); the fair value is what the company's own numbers justify (kr 46.82). For BioGaia AB the two are kr 67.38 per share apart. That gap is exactly why we show both numbers side by side.
How much is BioGaia AB worth?
The market values BioGaia AB at about 9.8B SEK (market capitalisation, as of Sep 24, 2026). Per share that is kr 114.20; our models calculate a fair value of kr 46.82 per share.
What do the bullish and bearish scenarios say about 0GTN?
Our models span a range for BioGaia AB: cautious scenario kr 35.12, base kr 46.82, optimistic kr 58.53 per share (as of Sep 24, 2026, price kr 114.20). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of BioGaia AB (0GTN)?
Balance-sheet figures for BioGaia AB (as of Sep 24, 2026): return on equity 30.8%. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is 0GTN from its 52-week high?
BioGaia AB trades at kr 114.20, about 16% below its 52-week high of kr 135.33 and 19% above the low of kr 95.58 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of kr 46.82 is for.
Which stocks are comparable to BioGaia AB?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BioGaia AB stock attractive at the current price?
The data as of Sep 24, 2026: price kr 114.20, calculated fair value kr 46.82 (−59%), Quality Score 64/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0GTN calculated?
We run BioGaia AB through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 46.82, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. BioGaia AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BioGaia AB (0GTN)?
The closing price on Oct 2, 2026 was kr 114.20. Our model-based fair value is kr 46.82, about −59% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BioGaia AB right now?
The price sits above even our optimistic bull case (kr 58.53). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of BioGaia AB
How large is the market capitalisation of BioGaia AB (0GTN)?
The market capitalisation of BioGaia AB is 9.8B SEK (≈ $973M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BioGaia AB (0GTN)?
The price-to-sales ratio of BioGaia AB is 6.18 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of BioGaia AB (0GTN)?
The dividend yield of BioGaia AB is 1.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of BioGaia AB (0GTN)?
The net margin of BioGaia AB is 24.1% (fiscal year 2020). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BioGaia AB (0GTN)?
The return on equity (ROE) of BioGaia AB is 30.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BioGaia AB (0GTN)?
On an EBIT basis the return on assets of BioGaia AB is 34.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BioGaia AB (0GTN)?
The operating margin of BioGaia AB is 28.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BioGaia AB (0GTN)?
Revenue at BioGaia AB is growing +8.9% versus a year earlier (3y avg +6.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at BioGaia AB (0GTN)?
Earnings per share at BioGaia AB are growing +17.4% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch BioGaia AB in the live analysis
One click puts BioGaia AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
